Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PNMT | P11086 | 5/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422918 | 1.00 | KDM4E (0.49) | KDM4EPNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL915241 | 0.98 | KDM4E (0.47) | KDM4EPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL9216134 | 0.89 | KDM4E (0.53) | KDM4EASIC3DRD2CHRNA7 | |
| SCHEMBL20929568 | 0.88 | CD274 (0.51) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| Hydrochloric Acid SCHEMBL6954419 | 0.87 | KDM4E (0.52) | KDM4EASIC3DRD2CHRNA7 | |
| SCHEMBL4689086 | 0.84 | KDM4E (0.42) | KDM4ECHRNA7 | |
| SCHEMBL11744516 | 0.82 | KDM4E (0.47) | KDM4EDRD2DRD3CHRNA7 | |
| SCHEMBL25406033 | 0.79 | ASIC3 (0.56) | KDM4EPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6635606 | 0.79 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL32660184 | 0.75 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5919794-A | Methods of using pharmaceutical tetrahydroisoquinolines | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-06 | — | — | US | claimed |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12428428-B2 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230140679-A1 | TRICYCLIC TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-5919794-A | Methods of using pharmaceutical tetrahydroisoquinolines | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0634401-B1 | MDR reversal agents | AMERICAN CYANAMID CO (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5639887-A | MULTIDRUG RESISTANT CELLS; INCREASE CELL SENSITIVITY TO ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | KDM4E 3328/4885PNMT 4649/4885ADRA2A 972/4885 |
| US-12428428-B2 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | CYP19A1, GPER1, HSD17B11 | KDM4E 3096/4885PNMT 2716/4885ADRA2A 843/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | KDM4E 3377/4885PNMT 4720/4885ADRA2A 1079/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | KDM4E 3377/4885PNMT 4720/4885ADRA2A 1079/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | KDM4E 1433/4885PNMT 4052/4885ADRA2A 4473/4885 |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TFEB, SNCA, PARK7 | KDM4E 2547/4885PNMT 3144/4885ADRA2A 1378/4885 |
| US-20230140679-A1 | TRICYCLIC TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | CYP19A1, GPER1, HSD17B11 | KDM4E 3096/4885PNMT 2716/4885ADRA2A 843/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | KDM4E 3328/4885PNMT 4649/4885ADRA2A 972/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | KDM4E 2973/4885PNMT 323/4885ADRA2A 7/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | KDM4E 3377/4885PNMT 4720/4885ADRA2A 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.